Introduction
Patients and methods
Several studies have shown that cefuroxime is effective in the treatment of gonorrhoea caused both by strains ofNeisseria gonorrhoeae that do not produce f lactamase and those that do. [1] [2] [3] Cefuroxime axetil is an ester prodrug of cefuroxime and is well absorbed after oral administration. The ester linkage in cefuroxime axetil is presumed to be hydrolysed in the intestinal mucosa during absorption, as only cefuroxime was detected in the peripheral circulation of volunteers. 4 The activity of cefuroxime against N gonorrhoeae combined with the pharmacokinetic properties of the prodrug have suggested that cefuroxime axetil would be an effective oral treatment for acute gonococcal urethritis.
We report a study of the efficacy and tolerance of single oral doses of cefuroxime axetil compared with oral ampicillin for treating acute uncomplicated gonorrhoea in men and women.
We studied men and women outpatients who attended the department of genitourinary medicine, Royal Hospital, Wolverhampton, who showed clinical signs and symptoms consistent with a diagnosis ofgonococcal infection or were the female sexual contacts ofinfected men. Allergy to penicillins or cephalosporins, requirement for concurrent antibiotics, and suppressive antimicrobial treatment within the four weeks preceeding the study were all reasons for exclusion. All pregnant or lactating women were excluded as was any patient who was thought to be unlikely to return for follow up visits. The study protocol was approved by the hospital ethics review committee, and informed consent was obtained from all patients.
On attendance at the clinic, the symptoms and clinical findings were noted, and smears were taken from the urethra and cervix. Rectal smears were taken from male homosexuals and from female partners of men with gonorrhoea. Smears were examined microscopically for the detection ofNgonorrhoeae as Gram negative intracellular diplococci. Materials from the same anatomical sites (and the pharynx when indicated) were cultured for N gonorrhoeae on modified Thayer-Martin medium. At the second attendance (first follow up) the patients were asked about symptoms, sexual contacts since their first visit, and adverse reactions (whether related to the drug or not) that had occurred after the treatment. Material for microscopy and culture was taken from the previously infected sites and a two glass urine test was taken. The same schedule was followed at the third visit.
Clinical assessment was made at the first follow up visit. Cure was defined by negative findings on both microscopy and culture. Failure was defined by persistence of gonococci on microscopy or culture, or both, at any initially infected site. Patients were excluded from the comparison of efficacy if they did not return for the first follow up visit, they had had sexual contact with untreated partners and the evidence from contact tracing supported the view that these patients had probably been reinfected, or they had concurrent primary syphilis.
At the second follow up visit, assessable patients whose urethral discharge had persisted or recurred after the eradication of gonorrhoea were diagnosed as Chlamydiae were detected at the first visit in 12 out of 55 men given ampicillin and six men given cefuroxime axetil (no significant difference by Fisher's exact test). Postgonococcal urethritis, however, was found at the second visit in 30 (54%) men given ampicillin and 19 (34%) men given cefuroxime axetil, which was a significant difference between drugs (p<005). The women were not tested for chlamydiae.
Both cefuroxime axetil and ampicillin were well tolerated. The only adverse events that we thought were related to ampicillin occurred in two women, one of whom developed generalised itching and the other vomited four hours after treatment. After receiving cefuroxime axetil two men and one woman had minor transient gastrointestinal disturbances. 
